摘要
目的:探讨索拉非尼二联疗法与三联疗法治疗早期肝癌的疗效差异。方法:选取42例早期肝癌患者为研究对象,按照随机数表法分为两组,对照组患者应用索拉非尼二联疗法方案治疗,观察组患者应用索拉非尼三联疗法方案治疗。采用实体瘤mRESIST评价标准对患者疗效进行评价,统计两组患者治疗后并发症发生情况,检测两组治疗前后血清血管内皮生长因子(VEGF)、骨桥素(OPN)、结缔组织生长因子(CTGF)水平。结果:观察组患者临床疗效总有效率显著高于对照组,差异有统计学意义(P<0.05)。观察组患者治疗后并发症发生率为14.29%,明显低于对照组的38.10%,差异有统计学意义(P<0.05)。两组患者治疗前血清VEGF、OPN、CTGF指标水平差异无统计学意义(P>0.05),观察组患者治疗后血清VEGF、OPN、CTGF指标水平显著低于对照组,差异有统计学意义(P<0.05)。两组患者3年总生存率分别为0.900、0.684,差异有统计学意义(P<0.05)。结论:索拉非尼三联疗法治疗早期肝癌患者能获得良好的临床疗效,且并发症较少,预后较好,能够改善早期肝癌患者血清指标水平。
Objective:To explore the difference between the efficacy of sorafenib dual therapy and triple therapy in the treatment of early liver cancer.Methods:Forty-two patients with early liver cancer who were treated in our hospital from October 2016 to October 2018 were selected as the research object,and were divided into two groups according to the random number table method.Sorafenib triple therapy program.Using solid tumor mRESIST evaluation criteria to evaluate the treatment effect of patients,statistics of the occurrence of complications after treatment in the two groups of patients,detection of serum vascular growth factor(VEGF),osteopontin(OPN),connective tissue growth factor(CTGF)indicator level.Results:A total of three CRs,nine PRs,and five SDs was observed in the observation group.A total of two CRs,seven PRs,and two SDs were found in the control group.The total clinical efficacy rate of the observation group was significantly higher than that of the control group.Significance(P<0.05).The incidence of complications in the observation group after treatment was 14.29%,which was significantly lower than that in the control group,38.10%,the difference was statistically significant(P<0.05).The levels of serum VEGF,OPN,and CTGF indicators before treatment in the two groups were not statistically significant(P>0.05).The levels of serum VEGF,OPN,and CTGF indicators in the observation group after treatment were significantly lower than those in the control group.The data comparison is statistically significant(P<0.05).The three-year overall survival rates of the two groups were 0.900 and 0.684,respectively.The observation group was significantly larger than the control group,and the difference was significant(P<0.05).Conclusion:Sorafenib triple therapy can achieve good clinical efficacy in the treatment of early liver cancer,and there are few complications after treatment,the prognosis quality is high,and it can improve the serum index level of early liver cancer patients.
作者
赵旭
程宁
纪民
李本科
吕婷婷
ZHAO Xu;CHENG Ning;JI Min(Department of interventional therapy,the Sixth People's Hospital of Dalian(Dalian,Liaoning,116003),China.)
出处
《中西医结合肝病杂志》
CAS
2021年第5期418-420,共3页
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
基金
辽宁省科技厅基金项目(No.20170540209)。
